{
  "id": 16633500,
  "title": "Bristol Myers Squibb: Bargain Buy or Value Trap?",
  "url": "https://urgent.news/2026/10/26/bristol-myers-squibb-bargain-buy-or-value-trap",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-26T17:08:01.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/26/bristol-myers-squibb-bargain-buy-or-value-trap/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Bristol Myers Squibb (BMY) is a prominent name in the healthcare industry, boasting a market capitalization of approximately $125 billion. However, over the past five years, the stock has only delivered returns of 6%, faring poorly compared to the S&P 500's impressive 70% growth over the same period. Bristol Myers has faced skepticism due to uncertainty surrounding its future growth, leading to a low valuation and an attractive yield. The management has categorized its products into legacy and growth portfolios to demonstrate that the company is not in as dire a situation as initially perceived.\n\nDuring the first half of the year, the legacy portfolio saw a 6% revenue decline, excluding foreign exchange effects, while the growth portfolio experienced a 12% organic growth rate. Despite this, the growth portfolio now surpasses the legacy portfolio in terms of revenue, generating $13.8 billion in sales compared to $10.7 billion. The company's top-line growth has been modest, with an organic growth rate of just 3% over this period. However, the performance of the growth portfolio has boosted investor confidence, resulting in a nearly 14% increase in Bristol Myers' stock price this year, slightly surpassing the S&P 500's 12% growth.\n\nWhile Bristol Myers stock has outperformed the market this year, its valuation remains remarkably low, trading at just nine times its estimated future earnings, which is significantly lower than the S&P 500's average multiple of 19. The company has faced challenges due to patent expirations, common among drug manufacturers, but its growth-focused portfolio has allowed it to perform relatively well given the circumstances. The stock's low valuation provides investors with a substantial margin of safety, and its high-yielding dividend, currently at 4.1% with a sustainable payout ratio of around 55%, adds to its appeal. Bristol Myers is, therefore, a stock that can be considered a bargain, and it is an excellent choice for long-term investors looking to purchase during this opportune moment.",
  "summary": "The healthcare stock trades at a forward earnings multiple of just nine, and its growth rate has been in the low single digits this year.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Bristol Myers Squibb: Bargain Buy or Value Trap?",
        "url": "https://urgent.news/2026/10/26/bristol-myers-squibb-bargain-buy-or-value-trap-16641996",
        "published": "2026-10-26T17:28:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}